The isoflavone metabolite dehydroequol produces vasodilatation in human resistance arteries via a nitric oxide-dependent mechanism

被引:27
作者
Chin-Dusting, JPF
Boak, L
Husband, A
Nestel, PJ
机构
[1] Baker Heart Res Inst, Alfred & Baker Med Unit, Prahran, Vic 3181, Australia
[2] Novogen Ltd, N Ryde, NSW 2113, Australia
关键词
isoflavone metabolite; dehydroequol; nitric oxide; human;
D O I
10.1016/j.atherosclerosis.2004.03.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Isoflavones (phytoestrogens) offer potential cardioprotective benefits. We recently reported on the vasodilatory activity of the isoflavone metabolite, dehydroequol, in rat isolated aortic ring preparations. In the current study, we examine the effect of this metabolite on the vascular haemodynamic profile in human forearm resistance arteries. Methods and results: Responses to brachial artery infusion of dehydroequol (0.1, 0.3, 1 and 3 mumol/min) in forearm resistance arteries were obtained in six healthy males. These were done, on two separate occasions, in the absence and presence of endogenous nitric oxide synthase inhibition using N-G-monomethyl-l-arginine, with sufficient sodium nitroprusside to maintain vascular tone. Dehydroequol produced a dose-dependent increase in forearm blood flow from 2.44 +/- 0.37 (basal) to 5.25 +/- 1.07 mL/100 mL/min (P < 0.05) at dehydroequol 3 mumol/min. Responses to dehydroequol were significantly dampened with inhibition of endogenous nitric oxide synthase (at 3 mumol/min: % increase in forearm blood flow fell from 114.3 +/- 22.81 to 19.45 +/- 9.19; P < 0.01). Conclusion: This is the first report of dehydroequol, a metabolite derived from the isoflavone diadzein, demonstrating potent vasodilatory properties in human resistance arteries via a nitric oxide-dependent mechanism. (C) 2004 Published by Elsevier Ireland Ltd.
引用
收藏
页码:45 / 48
页数:4
相关论文
共 11 条
[1]   Potential tissue selectivity of dietary phytoestrogens and estrogens [J].
Cassidy, A .
CURRENT OPINION IN LIPIDOLOGY, 1999, 10 (01) :47-52
[2]   The vascular activity of some isoflavone metabolites: implications for a cardioprotective role [J].
Chin-Dusting, JPF ;
Fisher, LJ ;
Lewis, TV ;
Piekarska, A ;
Nestel, PJ ;
Husband, A .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 (04) :595-605
[3]   NITRIC-OXIDE FUNCTIONS AS AN INHIBITOR OF PLATELET-ADHESION UNDER FLOW CONDITIONS [J].
DEGRAAF, JC ;
BANGA, JD ;
MONCADA, S ;
PALMER, RMJ ;
DEGROOT, PG ;
SIXMA, JJ .
CIRCULATION, 1992, 85 (06) :2284-2290
[4]   NITRIC OXIDE-GENERATING VASODILATORS AND 8-BROMO-CYCLIC GUANOSINE-MONOPHOSPHATE INHIBIT MITOGENESIS AND PROLIFERATION OF CULTURED RAT VASCULAR SMOOTH-MUSCLE CELLS [J].
GARG, UC ;
HASSID, A .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (05) :1774-1777
[5]  
Gimbrone MA, 1997, J CLIN INVEST, V100, pS61
[6]   Cardiovascular protective effects of synthetic isoflavone derivatives in apolipoprotein E-deficient mice [J].
Jiang, F ;
Jones, GT ;
Husband, AJ ;
Dusting, GJ .
JOURNAL OF VASCULAR RESEARCH, 2003, 40 (03) :276-284
[7]   LONG-TERM INHIBITION OF NO SYNTHESIS PROMOTES ATHEROSCLEROSIS IN THE HYPERCHOLESTEROLEMIC RABBIT THORACIC AORTA - PGH(2) DOES NOT CONTRIBUTE TO IMPAIRED ENDOTHELIUM-DEPENDENT RELAXATION [J].
NARUSE, K ;
SHIMIZU, K ;
MURAMATSU, M ;
TOKI, Y ;
MIYAZAKI, Y ;
OKUMURA, K ;
HASHIMOTO, H ;
ITO, T .
ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (05) :746-752
[8]   Cyclosporin A increases nitric oxide activity in vivo [J].
Stroes, ESG ;
Luscher, TF ;
deGroot, FG ;
Koomans, HA ;
Rabelink, TJ .
HYPERTENSION, 1997, 29 (02) :570-575
[9]  
VALLANCE P, 1989, LANCET, V2, P997
[10]   Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade [J].
Verhaar, MC ;
Strachan, FE ;
Newby, DE ;
Cruden, NL ;
Koomans, HA ;
Rabelink, TJ ;
Webb, DJ .
CIRCULATION, 1998, 97 (08) :752-756